Advertisement

International Journal of Hematology

, Volume 108, Issue 5, pp 516–523 | Cite as

Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma

  • Jun Nakashima
  • Yoshitaka Imaizumi
  • Hiroaki Taniguchi
  • Koji Ando
  • Masako Iwanaga
  • Hidehiro Itonaga
  • Shinya Sato
  • Yasuhi Sawayama
  • Tomoko Hata
  • Shinichiro Yoshida
  • Yukiyoshi Moriuchi
  • Yasushi Miyazaki
Original Article
  • 197 Downloads

Abstract

Adult T-cell leukemia–lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood. We analyzed the associations of clinical factors with the outcome after Moga treatment. Forty-five patients treated with Moga monotherapy were evaluated. The median age of the patients was 69 years, and 40% were female. The median overall survival (OS) time was 17.6 months and the 2-year OS rate was 43.2%. Number of prior therapies and response to prior therapy were predictive clinical features in univariate analysis for OS. Performance status, corrected serum calcium level, serum lactate dehydrogenase level, Japan Clinical Oncology Group-prognostic index (PI), and simplified ATL-PI at Moga treatment were also associated with the prognosis after Moga monotherapy. Improved understanding of the clinical factors predicting the prognosis after Moga may contribute to improved treatment strategies for ATL.

Keywords

ATL Mogamulizumab Prognostic factors 

Notes

Acknowledgements

We thank the hematologists in the Department of Hematology, Nagasaki University Hospital, National Hospital Organization Nagasaki Medical Center, and Sasebo City General Hospital, for the diagnosis and treatment of patients with ATL. We would like to thank Editage (http://www.editage.jp) for English language editing.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Supplementary material

12185_2018_2509_MOESM1_ESM.doc (96 kb)
Supplementary material 1 (DOC 96 KB)

References

  1. 1.
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428–37.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Taniguchi H, Imaizumi Y, Makiyama J, Itonaga H, Ando K, Sawayama Y, et al. Outcome of patients with relapsed/refractory adult T-cell leukemia-lymphoma after salvage therapy. Rinsho Ketsueki. 2013;54(12):2159–66.PubMedGoogle Scholar
  4. 4.
    Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99:1505–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, et al. A multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17:23–30.e2.CrossRefPubMedGoogle Scholar
  8. 8.
    Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, et al. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017;98:501–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Tokunaga M, Yonekura K, Nakamura D, Haraguchi K, Tabuchi T, Fujino S, et al. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. Br J Haematol. 2017.  https://doi.org/10.1111/bjh.14634.CrossRefPubMedGoogle Scholar
  10. 10.
    Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in Relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166:739–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108:2022–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ishitsuka K, Yurimoto S, Kawamura K, Tsuji Y, Iwabuchi M, Takahashi T, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. Int J Hematol. 2017;106(4):522–32.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Jun Nakashima
    • 1
    • 2
  • Yoshitaka Imaizumi
    • 3
  • Hiroaki Taniguchi
    • 4
  • Koji Ando
    • 1
  • Masako Iwanaga
    • 5
  • Hidehiro Itonaga
    • 3
  • Shinya Sato
    • 3
  • Yasuhi Sawayama
    • 3
  • Tomoko Hata
    • 1
  • Shinichiro Yoshida
    • 2
  • Yukiyoshi Moriuchi
    • 4
  • Yasushi Miyazaki
    • 1
    • 3
  1. 1.Atomic Bomb Disease and Hibakusha Medicine Unit, Department of HematologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  2. 2.Department of HematologyNational Hospital Organization Nagasaki Medical CenterNagasakiJapan
  3. 3.Department of HematologyNagasaki University HospitalNagasakiJapan
  4. 4.Department of HematologySasebo City General Medical CenterNagasakiJapan
  5. 5.Department of Frontier Life ScienceNagasaki University Graduate School of Biomedical ScienceNagasakiJapan

Personalised recommendations